Therapeutic Solutions International
Announces Preliminary Data for Immune
Stimulation in Advanced Cancer Patients by
Commercially Available Product
NanoStilbene Shown to Enhance Anticancer
Immunity in Cancer Patients
through Modulation of Inflammatory Mediators
OCEANSIDE, CA
-- January
14,
2019 -- InvestorsHub
NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
today early results of a
clinical trial suggesting efficacy of its product NanoStilbene in
increased activity of immune system
cells termed "Natural Killer" cells in advanced cancer
patients, as well as
enhancing production of interferon gamma, a protein associated with
suppression of cancer growth.
The study assessed
whether the
administration of
NanoStilbene, a nanoformulation of pterostilbene, is effective at
reducing inflammatory markers and augmenting immune function in
12 advanced
cancer
patients.
It has previously
been known that pterostilbene possesses direct anticancer activity
in the majority of cancers including melanoma1,
glioma2,
ovarian cancer3,
prostate cancer4,
pancreatic cancer5,
breast cancer6,
liver cancer7,
colorectal cancer8,
and various liquid tumors (leukemias)9.
"Chronic
inflammation, as measured by CRP, TNF-alpha and IL-6 levels in the
blood, has
been
reported to be immune suppressive in cancer
patients10
and we
sought to reduce them through orally administered
NanoStilbene," said Tim G Dixon CEO & President of Therapeutic
Solutions International, Inc. "On average we saw
CRP reduced by 27%, Interleukin 6 (IL-6) by 26% and TNF-alpha also
by 26%. This dramatic
reduction showed
clinically relevant
levels of downregulation of inflammatory cytokines as a result
of the
NanoStilbene
administration."
"The
suppression of
interferon gamma (IFN-g)
is a
hallmark of cancer immune evasion. Given that this cancer immune
evasion is typically associated with inflammatory mediators such as
TNF-alpha, we assessed the impact of NanoStilbene administration
on the
production of
interferon gamma. We observed an
average increase by 12% among the patients treated" said Dr. Thomas
Ichim, Director of
Therapeutic Solutions International.
"The
augmentation of interferon gamma production was due to the
reduction of pro-inflammatory cytokines CRP, TNF-a, and
IL-6, and we feel strongly
that patients should be on a 300mg dose of NanoStilbene
daily for
the
duration of their treatment, added Dr.
Ichim."
"The augmentation of
natural killer cell (NK)
activity
is one of the most sensitive indicators of anticancer
immunity we see
clinically. Previous studies
have shown that
efficacy
of antibody, as well as
chemotherapy-induced cancer cell death, is dependent on NK
activity. Unfortunately, cancer patients have suppressed NK
activity, usually as a result of oxidative stress, therefore, it
was postulated that NanoStilbene may reverse cancer associated NK
depression" said Dr. James
Veltmeyer, Chief Medical Officer of Therapeutic
Solutions International. "We
observed
on
average an increase
in
NK
activity of 37% in these very
sick patients, validating that 300mg of nanoparticle
pterostilbene (1.5
milliliters) daily was sufficient
to cause such dramatic results not usually seen even with FDA
approved drugs."
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
at
www.therapeuticsolutionsint.com
and our
e-commerce is at www.youcanordernow.com
and for
additional info on NanoStilbene visit www.nanostilbene.com.
1
https://nanostilbene.com/?page_id=361
2
https://nanostilbene.com/?page_id=344
3
https://nanostilbene.com/?page_id=367
4
https://nanostilbene.com/?page_id=371
5
https://nanostilbene.com/?page_id=369
6
https://nanostilbene.com/?page_id=328
7
https://nanostilbene.com/?page_id=355
8
https://nanostilbene.com/?page_id=340
9
https://nanostilbene.com/?page_id=353
10
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321727/
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
Safe Harbor
Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
Contact
Information: